DIVISLAB2024-04-012024-06-30 DIVISLAB2024-04-012024-06-30in-bse-fin:OneOperatingExpenses01Member DIVISLAB2024-06-30 DIVISLAB2024-04-012024-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member DIVISLAB2024-04-012024-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532488 DIVISLAB NOTLISTED Divi's Laboratories Limited Equity 2024-04-01 2025-03-31 2024-08-03 2024-07-25 INR Crores First quarter 10:45:00 12:00:00 2024-08-03 2024-08-03 Not applicable Single segment Manufacture of Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients 2024-04-01 2024-06-30 Unaudited Consolidated 21180000000.00 790000000.00 21970000000.00 8930000000.00 0.00 -400000000.00 2920000000.00 0.00 970000000.00 3510000000.00 15930000000.00 6040000000.00 0.00 6040000000.00 1790000000.00 -50000000.00 1740000000.00 0.00 4300000000.00 0.00 0.00 0.00 0.00 4300000000.00 10000000.00 4310000000.00 4300000000.00 0.00 4310000000.00 0.00 530000000.00 2 16.20 16.20 0.00 0.00 16.20 16.20 Earnings per Share calculated on actual amount of profit after tax in rupees Amount is below the rounding off norms adopted by the group. 1. The above Statement of Consolidated Unaudited Financial Results for the quarter ended 30th June, 2024 (“Statement”) has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The Statement is, as reviewed by the Audit Committee, considered and approved by the Board of Directors of the Company at its meeting held on 3rd August, 2024. The statutory auditors have carried out a limited review of the Statement and issued an unmodified report thereon. 2. The consolidated financial results include the financial results of Divi’s Laboratories Limited and its wholly owned two subsidiaries Divis Laboratories (USA) Inc. and Divi’s Laboratories Europe AG (Referred as the “Group”). 3. The Group is engaged in the manufacture of Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients; and the same constitutes a single reporting business segment as per Ind AS 108. 4. The Group does not have any discontinued operations and the Profit for the quarter represents the Profits from continuing operations only. 5. Details of Forex gain/(loss) are as given below: ( Rs. in Crores) Quarter Ended Year Ended 30.06.2024 31.03.2024 30.06.2023 31.03.2024 Forex gain/(loss) (1) (2) 3 30 Forex gain has been included in other income and loss has been included in other expenses. 6. **Figures for the quarter ended 31.03.2024 are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figures up to the third quarter of the respective financial year. Other Expenses 3510000000.00 Gain on Remeasurement of post-employment benefit obligations -10000000.00 -10000000.00 0.00 Gain on exchange differences in translating the financial statements of foreign operations 20000000.00 20000000.00 0.00